Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Operations: 2013-2024

Historic Cash from Operations for Wave Life Sciences (WVE) over the last 12 years, with Dec 2024 value amounting to -$151.0 million.

  • Wave Life Sciences' Cash from Operations rose 3.90% to -$44.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.4 million, marking a year-over-year decrease of 40.36%. This contributed to the annual value of -$151.0 million for FY2024, which is 677.24% down from last year.
  • Latest data reveals that Wave Life Sciences reported Cash from Operations of -$151.0 million as of FY2024, which was down 677.24% from -$19.4 million recorded in FY2023.
  • Over the past 5 years, Wave Life Sciences' Cash from Operations peaked at -$19.4 million during FY2023, and registered a low of -$151.0 million during FY2024.
  • Over the past 3 years, Wave Life Sciences' median Cash from Operations value was -$127.8 million (recorded in 2022), while the average stood at -$99.4 million.
  • In the last 5 years, Wave Life Sciences' Cash from Operations surged by 84.79% in 2023 and then plummeted by 677.24% in 2024.
  • Wave Life Sciences' Cash from Operations (Yearly) stood at -$116.0 million in 2020, then increased by 23.27% to -$89.0 million in 2021, then slumped by 43.59% to -$127.8 million in 2022, then spiked by 84.79% to -$19.4 million in 2023, then crashed by 677.24% to -$151.0 million in 2024.